All News
In early hip OA, look for underlying FAI (amongst other secondary causes. Surgical intervention however is very controversial.
@RheumNow #ACR22 #Pearls https://t.co/Gg4EtbnGiT
Julian Segan JulianSegan ( View Tweet)
Aggarwal @docrota et al. TYK2/JAK1i brepoctinib in dermatomyositis. Supportive clinical and pharmacological evidence, plus efficacy of other JAK agents, likely to lead to a clinical trial. @rheumnow #ACR22 Abstr#0157 https://t.co/Tz6dHfyUmq https://t.co/0R0tcuCe6D
Richard Conway RichardPAConway ( View Tweet)
"Behind the difficult to treat RA is a person!" Dr. Iris Navarro-Millán, MD reminds us to treat the patient, not just the disease! #ACR22 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
#RheumPearl FVC:DLCO ratio can be helpful to disting. b/t ILD and PAH. FVC:DLCO = 1 is seen in ILD. when the ratio > 1.6, typically assc with pulm vasc dz (e.g, PE, PAH) #ACR22 @rheumnow https://t.co/a7JJCLtv2N
TheDaoIndex KDAO2011 ( View Tweet)
🌟Subclinical GCA in PMR🌟
👉25pts PMR
👉US of TA and AX arteries
💥5(20%) US evidence of GCA (TA in 5/5, AX in 1/5)
💥1yr f/up -all 5 developed clinical GCA
❓Time to rethink our assessment of PMR pts ❓
Abst#0478
#ACR22 @RheumNow @colmkirby22
#ACRbest https://t.co/PynxF7wIck
Patricia Harkins DrTrishHarkins ( View Tweet)
Dr. Kolfenbach reminds us that scleritis isn't always red or painful! #ACR22 @RheumNow https://t.co/B5N0wE7LOL
Dr. Rachel Tate uptoTate ( View Tweet)
The next edition is in press. reserve your copy! Dr. Stone shared that he dedicated the book to his mom who died from SSc. #ACR22 @rheumnow https://t.co/i24lNAc7Qv
TheDaoIndex KDAO2011 ( View Tweet)
4/6 pts with PsA have poor sleep quality (!) (PSQI)
Asso w/ female, > enthesitis, > dis activity, fatigue, anxiety or depression.
1/2 = no ttmt for insomnia.
Multimodal interventions incl psychological support are key!
https://t.co/z5V9SKur3G
Abstr #0387 #ACR22 @Rheumnow https://t.co/CsTZkHjnn6
Aurelie Najm AurelieRheumo ( View Tweet)
Pearl: ANCA vasculitis may present initially as a migratory arthritis
@RheumNow #ACR22 #Pearls https://t.co/259ZNUcEMB
Julian Segan JulianSegan ( View Tweet)
Systemic autoimmune dx/'CTDs':
We attach lots of legacy labels, but most aren't pure/neatly in boxes.
We can do better:
immunophenotyping: FACS n=235 🇯🇵
unsupervised clustering
Within clusters: better phenotypes, varied labels.
This has to be the future
ABS0506 #ACR22 @RheumNow https://t.co/YUTVN1dWCh
David Liew drdavidliew ( View Tweet)
Kirby @colmkirby22 et al. US monitoring in newly diagnosed GCA. US mirrored clinical activity and predicted need for tocilizumab use. @rheumnow #ACR22 Abstr#0479 https://t.co/Ncqi8rZI6K https://t.co/DmzhNyzEfI
Richard Conway RichardPAConway ( View Tweet)
How age influence PsA clinical phenotype and diag?
Late onset PsA associated w/ male, > damage, > arthritis, > BASFI, < diag delay and < SI and enthesitis reports Puche-Larrubia et al from RESPONDIA & REGISPONSER registries.
https://t.co/pC21Yv8Nv9
Abstr #0377 #ACR22 @Rheumnow https://t.co/cQRDELO5my
Aurelie Najm AurelieRheumo ( View Tweet)
Complement TRENDS rather than absolute numbers may be more useful in pregnancy
@RheumNow #ACR22 #Pearls https://t.co/jz2SzdClfs
Julian Segan JulianSegan ( View Tweet)
Koc et al Female RA patients improve less in terms of disease activity over time. Score worse on HAQ,fatigue,SF-36 PCS, and morning stiffness duration @rheumnow #ACR22 Abstr#241 https://t.co/5HA0m3hNG4 https://t.co/Dx3C9r7FTl
Richard Conway RichardPAConway ( View Tweet)
@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D.
Not so surprising considering higher ratio for Fibromyalgia in W
ASDAS not asso w/ gender in AxSPA.
https://t.co/kBxvAi5qZw
Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l
Aurelie Najm AurelieRheumo ( View Tweet)
We've never been convinced on adjunct therapy in GCA - yet we're still worried about aortic dilatation.
Beta-blockers we're def not doing - but impressive retrospective data here.
Let's test this properly!
ABST0477 #ACR22 @RheumNow
(also @seminarthrheum https://t.co/onKW2JKIzo) https://t.co/yHTx29NJNX
David Liew drdavidliew ( View Tweet)
Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089
Continued under-reporting of race and ethnicity in PsA trials. Abs 0090
We can do better #rheumtwitter
#ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Germany based 74 pt #FMF prospective non-interventional, multicenter observational study on Canakinumab - RELIANCE Registry
63% in remission in 2 yrs
serious adverse drug reactions - 1.56 per 100 patient years
@RheumNow #ACR22 abst#0138
Bella Mehta bella_mehta ( View Tweet)
@ericdeinmd is moderating a great session, difficult to treat RA at #ACR22 right now! #rheumpix @RheumNow https://t.co/R5yg3eme6v
Dr. Rachel Tate uptoTate ( View Tweet)
Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/y7VWk3lOXD
Dr. John Cush RheumNow ( View Tweet)